Search

Your search keyword '"Bertani, L"' showing total 370 results
Start Over Author "Bertani, L"
370 results on '"Bertani, L"'

1. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

Author

Mengoli, C., Aronico, N., Lepore, F., Broglio, G., Merli, S., Natalello, G., Alimenti, E., Scalvini, D., Muscarella, S., Agustoni, F., Pagani, A., Chiellino, S., Corallo, S., Musella, V., Cannizzaro, R., Vecchi, M., Caprioli, F., Gabbiadini, R., Dal Buono, A., Premoli, A., Locati, L.D., Buda, A., Contaldo, A., Schiepatti, A., Biagi, F., Morano, D., Cucè, M., Kotsakis, A., De Lisi, G., Lenti, M.V., Ribaldone, D.G., Borrelli de Andreis, F., Vernero, M., Barberio, B., De Ruvo, M., Savarino, E.V., Kav, T., Blesl, A., Franzoi, M., Gröchenig, H.P., Pugliese, D., Ianiro, G., Porcari, S., Cammarota, G., Gasbarrini, A., Spagnuolo, R., Ellul, P., Foteinogiannopoulou, K., Koutroubakis, I., Argyriou, K., Cappello, M., Jauregui-Amezaga, A., Demarzo, M.G., Silvestris, N., Armuzzi, A., Sottotetti, F., Bertani, L., Festa, S., Eder, P., Pedrazzoli, P., Lasagna, A., Vanoli, A., Gambini, G., Santacroce, G., Rossi, C.M., Delliponti, M., Klersy, C., Corazza, G.R., and Di Sabatino, A.

Published
2024
Full Text
View/download PDF

2. OC.04.7: A ONE-YEAR FOLLOW-UP STUDY ON CHECKPOINT INHIBITORINDUCED COLITIS: RESULTS FROM A EUROPEAN CONSORTIUM

Author

Lenti, M.V., primary, Broglio, G., additional, Ribaldone, D.G., additional, Schiepatti, A., additional, Vernero, M., additional, Cosentino, F., additional, Blesl, A., additional, Buda, A., additional, Croitoru, A., additional, Del Buono, A., additional, Aranzazu Jaurgeu, A., additional, Lasagna, A., additional, Carvalho, D., additional, Pugliese, D., additional, Langholz, E., additional, Dahl, E., additional, Savarino, E.V., additional, Agustoni, F., additional, De Andreis, F. Borrelli, additional, Caprioli, F., additional, Schaik, F., additional, Sottotetti, F., additional, Cammarota, G., additional, Ianiro, G., additional, Gröchenig, H.P., additional, Koutroubakis, I., additional, Geldolf, J., additional, Argyriou, K., additional, Foteinogiannopolou, K., additional, Bertani, L., additional, Lobaton Ortega, T., additional, Cappello, M., additional, Delliponti, M., additional, Demarzo, M.G., additional, Truyens, M., additional, Silvestris, N., additional, Ellul, J., additional, Cannizzaro, R., additional, Gabbiadini, R., additional, Pedrazzoli, P., additional, Spagnuolo, R., additional, Saglio, S., additional, Stroie, T.G., additional, Natalello, G., additional, Varallo, M., additional, La Torre, M.A., additional, Petrucci, C., additional, Klersey, C., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2024
Full Text
View/download PDF

3. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

4. P965 Ulcerative proctitis treated with biologics: is it too hard to treat?

Author

Bertani, L, primary, Tricò, D, additional, Barberio, B, additional, Bretto, E, additional, Ceccarelli, L, additional, Calabrese, F, additional, Pasta, A, additional, Bertin, L, additional, Fabiana, Z, additional, Maniero, D, additional, Frara, S, additional, De Bernardi, A, additional, Bodini, G, additional, Ribaldone, D G, additional, Costa, F, additional, and Savarino, E V, additional

Published
2024
Full Text
View/download PDF

5. P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

Author

Bertani, L, primary, Tricò, D, additional, Barberio, B, additional, Vernero, M, additional, Bretto, E, additional, Ceccarelli, L, additional, Pardi, V, additional, Calabrese, F, additional, Pasta, A, additional, Bertin, L, additional, Fabiana, Z, additional, Semprucci, G, additional, Bodini, G, additional, Ribaldone, D G, additional, Savarino, E V, additional, and Costa, F, additional

Published
2024
Full Text
View/download PDF

9. P033 The assessment of serum cytokines at baseline could predict mucosal healing in patients with Crohn's disease treated with ustekinumab. A prospective study

Author

Bertani, L, primary, Antonioli, L, additional, Fornili, M, additional, D'Antongiovanni, V, additional, Coppini, F, additional, Ceccarelli, L, additional, Carmisciano, L, additional, Benvenuti, L, additional, Mumolo, M G, additional, Bottari, A, additional, Baglietto, L, additional, Bellini, M, additional, Fornai, M, additional, De Bortoli, N, additional, and Costa, F, additional

Published
2023
Full Text
View/download PDF

11. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

17. NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab

Author

Re KA, Marrazza M, Bertani L, Lurati A, Scarpellini M, and Bompane D

Subjects
Medicine (General), R5-920
Abstract

Alfredomaria Lurati, Luca Bertani, Mariagrazia Marrazza, Katia Angela Re, Daniela Bompane, Magda ScarpelliniRheumatology Unit, Fornaroli Hospital, Magenta, ItalyPurpose: The relationship between antiCD20 therapy with rituximab and the lymphocytes phenotype in patients with rheumatoid arthritis was investigated, with an attempt to establish a relationship between commonly used clinical activity indices and variations in leukocyte count, in particular natural killer (NK) lymphocytes.Methods: Patients with seropositive (cyclic citrullinated peptides and rheumatoid factor positive) rheumatoid arthritis (according to the American College of Rheumatology 1987 criteria) refractory to conventional and antitumor necrosis factor-alpha agents who were subsequently treated with rituximab, a chimeric monoclonal antibody directed against CD20, were enrolled between January 2009 and September 2009. All subjects were treated with rituximab standard rheumatologic dose of 1.0 g on days 1 and 15 every 6 months for at least 2 years. A clinical evaluation was performed at baseline and subsequently every 3 months thereafter. At each assessment activated NK (CD56+/CD16+/CD54bright) cell count was collected and disease activity was assessed using Disease Activity Score in 28 Joints and the Simplified Disease Activity Index (SDAI).Results: Thirty-four patients were enrolled (mean age ± standard deviation: 54.8 ± 12.8 years). Basal SDAI was 21.75 ± 5.4 and NK cell count mean value was 157.6 ± 90. After 24 months, SDAI was 14 ± 1.2 and NK cell count mean value was 301.7 ± 21 (P < 0.05). An inverted correlation between SDAI and NK count was observed at 3 months (r = -0.36, P < 0.05), 6 months (r = -0.48, P < 0.45), 9 months (r = -0.47, P < 0.05), 12 months (r = -0.41, P < 0.01), 15 months (r = -0.58, P < 0.05), 18 months (r = -0.53, P < 0.05), 21 months (r = -0.68, P < 0.05), and 24 months (r = -0.61, P < 0.05). A linear regression model between all variables collected and SDAI/Disease Activity Score in 28 Joints at 6 months and 12 months confirmed a significant relationship between SDAI/Disease Activity Score in 28 Joints and NK cell count.Conclusion: The data confirm the clinical efficacy of rituximab and suggests the use of NK cells as a predictor of clinical response in patients with rheumatoid arthritis.Keywords: NK cells, rituximab, predictor, response, rheumatoid arthritis

Published
2012

18. P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series

Author

Barberio, B, primary, Savarino, E, additional, Verstockt, B, additional, Fumery, M, additional, Pugliese, D, additional, Bertani, L, additional, Buda, A, additional, Dragoni, G, additional, Goren, I, additional, Laish, I, additional, Spinelli, A, additional, Teich, N, additional, Truyens, M, additional, and Ellul, P, additional

Published
2022
Full Text
View/download PDF

21. AF.47 HOSPITALIZATION FOR DRUG INFUSION DOES NOT INCREASE COVID INFECTION RATE, IBD RELAPSES DUE TO INFECTIONS AND LEVELS OF ANXIETY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY

Author

Bertani, L., primary, Barberio, B., additional, Tricò, D., additional, Zanzi, F., additional, Maniero, D., additional, Ceccarelli, L., additional, Marsilio, I., additional, Minciotti, M., additional, Coppini, F., additional, Lorenzon, G., additional, Mumolo, M.G., additional, Zingone, F., additional, Costa, F., additional, and Savarino, E.V., additional

Published
2021
Full Text
View/download PDF

22. OC.09.2 VITAMIN D-RELATED GENETICS AS PREDICTOR OF RESPONSE TO ADALIMUMAB IN CROHN’S DISEASE

Author

Cusato, J., primary, Bertani, L., additional, Antonucci, M., additional, Tomasello, C., additional, Caviglia, G.P., additional, Dibitetto, S., additional, Massano, A., additional, Mangia, M., additional, Mula, J., additional, Ceccarelli, L., additional, Costa, F., additional, Zanzi, F., additional, Astegiano, M., additional, Ribaldone, D.G., additional, and D’avolio, A., additional

Published
2021
Full Text
View/download PDF

25. AF.55 ADHERENCE TO MESALAZINE AND IDENTIFICATION OF PATIENTS WITH ULCERATIVE COLITIS IN HEALTHCARE ADMINISTRATIVE DATABASES OF TUSCANY (ITALY)

Author

Bertani, L., primary, Bartolini, C., additional, Ferraro, S., additional, Convertino, I., additional, Giometto, S., additional, Tillati, S., additional, Valdiserra, G., additional, Cappello, E., additional, Blandizzi, C., additional, Lucenteforte, E., additional, Gini, R., additional, Tuccori, M., additional, and Costa, F., additional

Published
2021
Full Text
View/download PDF

26. AF.58 DIAGNOSTIC DELAY, EFFECTIVENESS AND SAFETY OUTCOMES IN A REAL-WORLD COHORT OF PATIENTS WITH CROHN’S DISEASE: DATA FROM ADMINISTRATIVE DATABASES IN TUSCANY, ITALY

Author

Bertani, L., primary, Ferraro, S., additional, Bartolini, C., additional, Convertino, I., additional, Giometto, S., additional, Cappello, E., additional, Valdiserra, G., additional, Tillati, S., additional, Blandizzi, C., additional, Lucenteforte, E., additional, Gini, R., additional, Tuccori, M., additional, and Costa, F., additional

Published
2021
Full Text
View/download PDF

34. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Author

Pugliese, Daniela, Guidi, Luisa, Privitera, Giuseppe, Bertani, L., Tolusso, Barbara, Papparella, Luigi Giovanni, Maltinti, S., Di Mario, Clara, Onali, Sebastiano, Ceccarelli, L., Rapaccini, Gian Ludovico, Scaldaferri, Franco, Gremese, Elisa, Gasbarrini, Antonio, Costa, F., Armuzzi, Alessandro, Pugliese D., Guidi L. (ORCID:0000-0003-3320-7094), Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Papparella L. G., Di Mario C., Onali S., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Scaldaferri F. (ORCID:0000-0001-8334-7541), Gremese E. (ORCID:0000-0002-2248-1058), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Pugliese, Daniela, Guidi, Luisa, Privitera, Giuseppe, Bertani, L., Tolusso, Barbara, Papparella, Luigi Giovanni, Maltinti, S., Di Mario, Clara, Onali, Sebastiano, Ceccarelli, L., Rapaccini, Gian Ludovico, Scaldaferri, Franco, Gremese, Elisa, Gasbarrini, Antonio, Costa, F., Armuzzi, Alessandro, Pugliese D., Guidi L. (ORCID:0000-0003-3320-7094), Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Papparella L. G., Di Mario C., Onali S., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Scaldaferri F. (ORCID:0000-0001-8334-7541), Gremese E. (ORCID:0000-0002-2248-1058), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)

Abstract

Background: Switching from IFX originator to CT-P13 is safe; however, little data on immunogenicity exists. Research design and methods: Consecutive IBD patients on IFX originator were switched to CT-P13 and followed-up for 12 months. Clinical activity, infliximab trough levels (ITLs), anti-drug antibodies (ATIs), and adverse events were recorded at predefined timepoints (baseline, second CT-P13 infusion, 6 and 12 months). The outcomes investigated were immunogenicity, pharmacokinetics, effectiveness and safety. Results: 119 patients were switched to CT-P13 after a median time with IFX of 5.8 years. No changes in mean ITLs were observed. ATIs were detected in 30 patients (25.2%): 14 before and 16 after switch. Mean persistent ATIs were significantly higher compared to mean transient ones (109.74 ng/mL ±84.70 vs 18.22 ng/mL ±11.37, p < 0.001), with significantly lower ITLs associated (mean 0.32 µg/mL ±0.6 vs 3.08 µg/mL ±3.22, p < 0.001). A significant decrease of patients in steroid-fee clinical remission was observed after the switch (p = 0.004), with subsequent improvement at 6 months (p = 0.005). Eighteen patients (15.1%) discontinued IFX, only 6 (5%) for loss of response. Conclusions: Switching from infliximab originator to CT-P13 seems safe and effective, without differences in immunogenicity. A temporary reduction of clinical benefit after switching could be potentially explained by a ‘nocebo-effect response’.

Published
2021

36. P651 Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn’s disease: data from administrative databases in Tuscany, Italy

Author

Bertani, L, primary, Ferraro, S, additional, Bartolini, C, additional, Convertino, I, additional, Giometto, S, additional, Cappello, E, additional, Valdiserra, G, additional, Tillati, S, additional, Blandizzi, C, additional, Lucenteforte, E, additional, Gini, R, additional, Tuccori, M, additional, and Costa, F, additional

Published
2021
Full Text
View/download PDF

40. P506 The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients

Author

Bertani, L, primary, Barberio, B, additional, Zanzi, F, additional, Maniero, D, additional, Ceccarelli, L, additional, Marsilio, I, additional, Minciotti, M, additional, Coppini, F, additional, Lorenzon, G, additional, Mumolo, M G, additional, Zingone, F, additional, Costa, F, additional, and Savarino, E V, additional

Published
2021
Full Text
View/download PDF

41. P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)

Author

Bertani, L, primary, Bartolini, C, additional, Ferraro, S, additional, Convertino, I, additional, Giometto, S, additional, Tillati, S, additional, Valdiserra, G, additional, Cappello, E, additional, Blandizzi, C, additional, Lucenteforte, E, additional, Gini, R, additional, Tuccori, M, additional, and Costa, F, additional

Published
2021
Full Text
View/download PDF

42. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome

Author

Gargari, G, Taverniti, V, Gardana, C, Cremon, C, Canducci, F, Pagano, I, Barbaro, M, Bellacosa, L, Castellazzi, A, Valsecchi, C, Tagliacarne, S, Bellini, M, Bertani, L, Gambaccini, D, Marchi, S, Cicala, M, Germana, B, Dal Pont, E, Vecchi, M, Ogliari, C, Fiore, W, Stanghellini, V, Barbara, G, Guglielmetti, S, Gargari G., Taverniti V., Gardana C., Cremon C., Canducci F., Pagano I., Barbaro M. R., Bellacosa L., Castellazzi A. M., Valsecchi C., Tagliacarne S. C., Bellini M., Bertani L., Gambaccini D., Marchi S., Cicala M., Germana B., Dal Pont E., Vecchi M., Ogliari C., Fiore W., Stanghellini V., Barbara G., Guglielmetti S., Gargari, G, Taverniti, V, Gardana, C, Cremon, C, Canducci, F, Pagano, I, Barbaro, M, Bellacosa, L, Castellazzi, A, Valsecchi, C, Tagliacarne, S, Bellini, M, Bertani, L, Gambaccini, D, Marchi, S, Cicala, M, Germana, B, Dal Pont, E, Vecchi, M, Ogliari, C, Fiore, W, Stanghellini, V, Barbara, G, Guglielmetti, S, Gargari G., Taverniti V., Gardana C., Cremon C., Canducci F., Pagano I., Barbaro M. R., Bellacosa L., Castellazzi A. M., Valsecchi C., Tagliacarne S. C., Bellini M., Bertani L., Gambaccini D., Marchi S., Cicala M., Germana B., Dal Pont E., Vecchi M., Ogliari C., Fiore W., Stanghellini V., Barbara G., and Guglielmetti S.

Abstract

Irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, is classified according to bowel habits as IBS with constipation (IBS-C), with diarrhea (IBS-D), with alternating constipation and diarrhea (IBS-M), and unsubtyped (IBS-U). The mechanisms leading to the different IBS forms are mostly unknown. This study aims to evaluate whether specific fecal bacterial taxa and/or short-chain fatty acids (SCFAs) can be used to distinguish IBS subtypes and are relevant for explaining the clinical differences between IBS subcategories. We characterized five fecal samples collected at 4-weeks intervals from 40 IBS patients by 16S rRNA gene profiling and SCFA quantification. Finally, we investigated the potential correlations in IBS subtypes between the fecal microbial signatures and host physiological and clinical parameters. We found significant differences in the distribution of Clostridiales OTUs among IBS subtypes and reduced levels of SCFAs in IBS-C compared to IBS-U and IBS-D patients. Correlation analyses showed that the diverse representation of Clostridiales OTUs between IBS subtypes was associated with altered levels of SCFAs; furthermore, the same OTUs and SCFAs were associated with the fecal cytokine levels and stool consistency. Our results suggest that intestinal Clostridiales and SCFAs might serve as potential mechanistic biomarkers of IBS subtypes and represent therapeutic targets.

Published
2018

43. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial

Author

Cremon, C, Guglielmetti, S, Gargari, G, Taverniti, V, Castellazzi, A, Valsecchi, C, Tagliacarne, C, Fiore, W, Bellini, M, Bertani, L, Gambaccini, D, Cicala, M, Germana, B, Vecchi, M, Pagano, I, Barbaro, M, Bellacosa, L, Stanghellini, V, Barbara, G, Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A. M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., Gambaccini D., Cicala M., Germana B., Vecchi M., Pagano I., Barbaro M. R., Bellacosa L., Stanghellini V., Barbara G., Cremon, C, Guglielmetti, S, Gargari, G, Taverniti, V, Castellazzi, A, Valsecchi, C, Tagliacarne, C, Fiore, W, Bellini, M, Bertani, L, Gambaccini, D, Cicala, M, Germana, B, Vecchi, M, Pagano, I, Barbaro, M, Bellacosa, L, Stanghellini, V, Barbara, G, Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A. M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., Gambaccini D., Cicala M., Germana B., Vecchi M., Pagano I., Barbaro M. R., Bellacosa L., Stanghellini V., and Barbara G.

Abstract

Background: Evidence suggests a role of intestinal microbiota-host interactions in the pathophysiology and symptoms of irritable bowel syndrome (IBS). Objective: The objective of this article is to assess the effects of Lactobacillus paracasei CNCM I-1572 on clinical and gut microbiota-related factors in IBS. Methods: We conducted a multicenter, randomized, double-blind, cross-over, 18-week, placebo-controlled, pilot trial assessing the effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota composition, fecal short chain fatty acid (SCFA), immunoglobulin A, and cytokines in IBS. The intestinal microbial ecosystem was characterized by 16S rRNA gene profiling. Results: Forty IBS patients were enrolled from five Italian centers. Lactobacillus paracasei CNCM I-1572 did not significantly improve IBS symptoms, including primary efficacy variables worst abdominal pain/discomfort and IBS degree of relief. Interestingly, Lactobacillus paracasei CNCM I-1572 induced a significant reduction in genus Ruminococcus, dominated by taxa related to Ruminococcus bromii and Ruminococcus callidus, a significant increase in the SCFAs acetate and butyrate, and a significant reduction in the pro-inflammatory cytokine interleukin-15. Conclusions: This pilot study shows that Lactobacillus paracasei CNCM I-1572 is able to modulate gut microbiota structure/function and reduce immune activation in IBS. As no statistically significant effect on IBS-symptoms was found, further studies are necessary to determine the role of this probiotic in IBS. The study was registered at ClinicalTrials.gov registry under identifier NCT02371499.

Published
2018

46. NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]

Author

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, and Scarpellini M

Subjects
Medicine (General), R5-920
Abstract

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M. Biologics: Targets and Therapy. 2012;6:83–87.On page 87, the disclosure was listed as ‘The authors report no conflicts of interest in this work.’ in error. The correct disclosure should be ‘An unrestricted publication grant was provided by Roche S.p.A. The authors have no other conflicts of interest to report.’Read the original article

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results